PureTech Health Plc engages in the provision of differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders. It operates through the following segments: Internal, Controlled Founded Entities, Non-Controlled Founded Entities, and Parent Company and Others. The Internal segment focuses on immunological, fibrotic, and lymphatic system mechanisms. The Controlled Founded Entities segment is composed of the group’s subsidiaries that are currently consolidated operational subsidiaries that either have or have plans to hire independent management teams and currently have already raised, or are currently in the process of raising, third-party dilutive capital. The Non-Controlled Founded Entities segment includes companies wherein the group no longer holds majority voting control as a shareholder and no longer has the right to elect a majority of the members of the subsidiaries’ Board of Directors. The Parent Company and Other segment represents activities that are not directly attributable to the operating segments, such as the activities of the parent, corporate support functions and certain research and development support functions that are not directly attributable to a strategic business segment as well as the elimination of intercompany transactions. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is Market Cap of PureTech Health Plc - ADR?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. PureTech Health Plc - ADR market cap is $775.57M.
What is the 52-week high for PureTech Health Plc - ADR?
52 week high is the highest price of a stock in the past 52 weeks, or one year. PureTech Health Plc - ADR 52 week high is $34.00 as of May 18, 2024.
What is the 52-week low for PureTech Health Plc - ADR?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. PureTech Health Plc - ADR 52 week low is $17.08 as of May 18, 2024.
What is PureTech Health Plc - ADR stock price today?
PureTech Health Plc - ADR stock price today is $28.68.
What was PureTech Health Plc - ADR stock price yesterday?
PureTech Health Plc - ADR stock price yesterday was $28.51.
What is the PE ratio of PureTech Health Plc - ADR?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. PureTech Health Plc - ADR’s P/E ratio is -12.12.
What is the Price-to-Book ratio of PureTech Health Plc - ADR?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. PureTech Health Plc - ADR P/B ratio is 1.6802.
What is PureTech Health Plc - ADR's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. PureTech Health Plc - ADR's EBITDA is -3.31.
What is the 50-day moving average of PureTech Health Plc - ADR?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. PureTech Health Plc - ADR 50-day moving average is $27.48.